Literature DB >> 18775293

Assays for the detection of recent infections with human immunodeficiency virus type 1.

G Murphy1, J V Parry.   

Abstract

The Serological Testing Algorithm for Recent HIV Seroconversion (STARHS) is a generic term for several laboratory techniques that can be used to differentiate recent from long standing infections with human immunodeficiency virus-1 (HIV-1). There are several other approaches that identify acute seroconverters, but STARHS methods are distinguished by their ability to identify infections that occurred during an extended period of 4-6 months prior to sampling. While the STARHS techniques have been employed on an individual basis, their main usefulness lies in the potential of estimating the rate of acquisition of new HIV infection, or incidence, in a population by application to cross-sectional sero-surveys. This is substantially simpler and less expensive than cohort studies. As such, STARHS techniques facilitate the timely monitoring of the impact on HIV incidence of factors such as interventions, demographic factors and behavioural patterns. The major STARHS techniques currently available are described. Furthermore, the principles behind the methods used are discussed and the limitations of the current assays and the confounding factors that may affect assay specificity are described. A model algorithm for the application of a STARHS assay is shown. Finally, we outline recommendations for laboratory quality systems that will improve the efficiency of STARHS testing, reproducibility of results and reliability of incidence estimates.

Entities:  

Mesh:

Year:  2008        PMID: 18775293

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  70 in total

1.  Factors associated with incorrect identification of recent HIV infection using the BED capture immunoassay.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Amy E Oliver; Caroline E Mullis; Kevin P Eaton; Amy C Mueller; Lisa P Jacobson; Joseph B Margolick; Joelle Brown; Charles R Rinaldo; Thomas C Quinn; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2011-12-01       Impact factor: 2.205

2.  Specificity of four laboratory approaches for cross-sectional HIV incidence determination: analysis of samples from adults with known nonrecent HIV infection from five African countries.

Authors:  Oliver Laeyendecker; Ron Brookmeyer; Caroline E Mullis; Deborah Donnell; Jairam Lingappa; Connie Celum; Jared M Baeten; Mary S Campbell; Max Essex; Guy de Bruyn; Carey Farquhar; Thomas C Quinn; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10       Impact factor: 2.205

3.  Short Communication: Defining optimality of a test for recent infection for HIV incidence surveillance.

Authors:  Reshma Kassanjee; Thomas A McWalter; Alex Welte
Journal:  AIDS Res Hum Retroviruses       Date:  2013-10-26       Impact factor: 2.205

4.  Short Communication: Comparison of Maxim and Sedia Limiting Antigen Assay Performance for Measuring HIV Incidence.

Authors:  Katherine E Schlusser; Jacob Konikoff; Allison R Kirkpatrick; Charles Morrison; Tsungai Chipato; Pai-Lien Chen; Marshall Munjoma; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2017-03-20       Impact factor: 2.205

5.  Short Communication: The Impact of Viral Suppression and Viral Breakthrough on Limited-Antigen Avidity Assay Results in Individuals with Clade B HIV Infection.

Authors:  Sarah K Wendel; Andrew F Longosz; Susan H Eshleman; Joel N Blankson; Richard D Moore; Jeanne C Keruly; Thomas C Quinn; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2017-01-11       Impact factor: 2.205

6.  Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation.

Authors:  Sheila M Keating; Debra Hanson; Mila Lebedeva; Oliver Laeyendecker; N'ko L Ali-Napo; S Michele Owen; Susan L Stramer; Richard D Moore; Philip J Norris; Michael P Busch
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

7.  Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays.

Authors:  Ethan Klock; George Mwinnya; Leigh Anne Eller; Reinaldo E Fernandez; Hannah Kibuuka; Sorachai Nitayaphan; Josphat Kosgei; Richard D Moore; Merlin Robb; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2020-05-27       Impact factor: 2.205

8.  Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an antibody avidity assay.

Authors:  Andrew F Longosz; Charles S Morrison; Pai-Lien Chen; Eric Arts; Immaculate Nankya; Robert A Salata; Veronica Franco; Thomas C Quinn; Susan H Eshleman; Oliver Laeyendecker
Journal:  J Acquir Immune Defic Syndr       Date:  2014-04-01       Impact factor: 3.731

9.  Prevalence, estimated HIV-1 incidence and viral diversity among people seeking voluntary counseling and testing services in Rio de Janeiro, Brazil.

Authors:  Carlos A Velasco de Castro; Beatriz Grinsztejn; Valdiléa G Veloso; Francisco I Bastos; José H Pilotto; Mariza G Morgado
Journal:  BMC Infect Dis       Date:  2010-07-28       Impact factor: 3.090

10.  Pregnancy does not affect HIV incidence test results obtained using the BED capture enzyme immunoassay or an antibody avidity assay.

Authors:  Oliver Laeyendecker; Jessica D Church; Amy E Oliver; Anthony Mwatha; S Michele Owen; Deborah Donnell; Ron Brookmeyer; Philippa Musoke; J Brooks Jackson; Laura Guay; Clemesia Nakabiito; Thomas C Quinn; Susan H Eshleman
Journal:  PLoS One       Date:  2010-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.